State Street Corp Grows Position in FibroBiologics, Inc. (NASDAQ:FBLG)

State Street Corp grew its stake in FibroBiologics, Inc. (NASDAQ:FBLG) by 26.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 475,837 shares of the company’s stock after acquiring an additional 99,789 shares during the quarter. State Street Corp’s holdings in FibroBiologics were worth $1,470,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new position in FibroBiologics in the 2nd quarter valued at about $342,000. Concurrent Investment Advisors LLC purchased a new stake in shares of FibroBiologics during the second quarter worth about $176,000. Rhumbline Advisers acquired a new position in shares of FibroBiologics in the second quarter valued at approximately $115,000. Cahaba Wealth Management Inc. acquired a new position in shares of FibroBiologics in the second quarter valued at approximately $73,000. Finally, Fund Evaluation Group LLC purchased a new position in shares of FibroBiologics during the second quarter valued at approximately $5,265,000.

FibroBiologics Price Performance

Shares of NASDAQ FBLG opened at $1.99 on Friday. The firm has a fifty day moving average of $2.59 and a 200-day moving average of $3.14. FibroBiologics, Inc. has a 52-week low of $1.08 and a 52-week high of $55.00.

Analysts Set New Price Targets

Several brokerages have weighed in on FBLG. D. Boral Capital reiterated a “buy” rating and issued a $16.00 price target on shares of FibroBiologics in a report on Friday, December 27th. Maxim Group assumed coverage on FibroBiologics in a research report on Tuesday, September 24th. They issued a “buy” rating and a $12.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of FibroBiologics in a research report on Wednesday, November 13th. Finally, Rodman & Renshaw began coverage on FibroBiologics in a report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.